4.5 Article

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

Journal

BLOOD CANCER JOURNAL
Volume 13, Issue 1, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41408-023-00790-1

Keywords

-

Ask authors/readers for more resources

Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reported in various cancers, including AML. Mutations of its STAG2 subunit were found to be associated with unfavorable risk in AML patients, but limited evidence and conflicting observations exist regarding their clinical outcomes. We analyzed data from 1615 AML patients and identified distinct co-mutational patterns for STAG2 mutations. We also found mutual exclusivity of genetic alterations in individual cohesin subunits, suggesting potential therapeutic strategies for cohesin mutated AML.
Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reported in a multitude of cancers including acute myeloid leukemia (AML). Mutations of its STAG2 subunit may predict unfavorable risk as recognized by the 2022 European Leukemia Net recommendations, but the underlying evidence is limited by small sample sizes and conflicting observations regarding clinical outcomes, as well as scarce information on other cohesion complex subunits. We retrospectively analyzed data from a multi-center cohort of 1615 intensively treated AML patients and identified distinct co-mutational patters for mutations of STAG2, which were associated with normal karyotypes (NK) and concomitant mutations in IDH2, RUNX1, BCOR, ASXL1, and SRSF2. Mutated RAD21 was associated with NK, mutated EZH2, KRAS, CBL, and NPM1. Patients harboring mutated STAG2 were older and presented with decreased white blood cell, bone marrow and peripheral blood blast counts. Overall, neither mutated STAG2, RAD21, SMC1A nor SMC3 displayed any significant, independent effect on clinical outcomes defined as complete remission, event-free, relapse-free or overall survival. However, we found almost complete mutual exclusivity of genetic alterations of individual cohesin subunits. This mutual exclusivity may be the basis for therapeutic strategies via synthetic lethality in cohesin mutated AML.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available